IP Library › Granted Patent US 12,195,514
Granted Patent B2
US 12,195,514 · App. 16/986,913 · Granted Jan 14, 2025

Chimeric antigen receptors and methods of use thereof

Inventor: Wayne A. Marasco (Wellsley, MA)
Assignee: Dana-Farber Cancer Institute, Inc.
C07K14/7051C07K14/705C07K14/70521C07K14/70535C07K14/70578C07K19/00C07K2319/02C07K2319/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,514
App. No.
16/986,913
Granted
Jan 14, 2025
Kind
B2
Abstract

The present invention provides chimeric antigen receptors, cells expressing same and methods of using same for treatment various disorders such as cancer.

Claims (12)

1. A nucleic acid encoding a chimeric antigen receptor (CAR) comprising an extracellular domain, a transmembrane domain, and an intracellular signaling domain, wherein a CD28 costimulatory domain is positioned between the transmembrane domain and the intracellular signaling domain; wherein the intracellular signaling domain comprises a CD3z primary signaling domain; and wherein the extracellular domain comprises an anti-carbonic anhydrase IX (anti-CAIX) scFv comprising a V H amino acid sequence according to SEQ ID NO: 847 and a V L amino acid sequence according to SEQ ID NO: 868, further comprising a nucleic acid encoding an anti-PDL1 IgG4 scFv-Fc or an anti-PDL1 IgG1 scFv-Fc positioned after the intracellular signaling domain.

2. A vector comprising the nucleic acid of claim 1 .

3. A cell comprising the vector of claim 2 .

4. The cell of claim 3 , wherein the cell is a T-cell or an NK cell.

5. The cell of claim 4 , wherein the T cell is CD4 + or CD8 + .

6. The nucleic acid of claim 1 , wherein the chimeric antigen receptor further comprises a stalk region positioned between the extracellular domain and the transmembrane domain.

7. The nucleic acid of claim 1 , wherein the transmembrane domain comprises a CD28 transmembrane domain.

8. A genetically engineered cell which expresses and bears on the cell surface membrane a chimeric antigen receptor comprising an extracellular domain, a transmembrane domain, and an intracellular signaling domain, wherein a CD28 costimulatory domain is positioned between the transmembrane domain and the intracellular signaling domain; wherein the intracellular signaling domain comprises a CD3z primary signaling domain; and wherein the extracellular domain comprises an anti-carbonic anhydrase IX (anti-CAIX) scFv comprising a V H amino acid sequence according to SEQ ID NO: 847 and a V L amino acid sequence according to SEQ ID NO: 868, wherein the cell is further engineered to express and secrete an anti-PDL1 IgG4 scFv-Fc or an anti-PDL1 IgG1 scFv-Fc.

9. The genetically engineered cell of claim 8 , wherein the cell is a T-cell or an NK cell.

10. The genetically engineered cell of claim 9 , wherein the T cell is CD4 + or CD8 + .

11. The genetically engineered cell of claim 8 , wherein the chimeric antigen receptor further comprises a stalk region positioned between the extracellular domain and the transmembrane domain.

12. The genetically engineered cell of claim 8 , wherein the transmembrane domain comprises a CD28 transmembrane domain.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2024
From: MARASCO, WAYNE A.
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 069484/0626 →
CONFIRMATORY LICENSE Recorded Jan 26, 2023
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062519/0972 →
Continuity (4)
Continuation 15537779
Provisional Application 62252083 · Nov 6, 2015
Provisional Application 62094625 · Dec 19, 2014
Related Publication 20210061877A1 · Mar 4, 2021
References Cited (136)
US 4683202A · Mullis · 1987 [cited by applicant]
US 4797368A · Carter et al. · 1989 [cited by applicant]
US 5139941A · Muzyczka et al. · 1992 [cited by applicant]
US 5928906A · Koester et al. · 1999 [cited by applicant]
US 5994136A · Naldini et al. · 1999 [cited by applicant]
US 6013516A · Verma et al. · 2000 [cited by applicant]
US 20210221906A1 · Marasco · 2021 [cited by examiner]
WO 2005044996 · 2005 [cited by applicant]
WO 2005060520 · 2005 [cited by applicant]
WO 2006089141 · 2006 [cited by applicant]
WO 2007065027 · 2007 [cited by applicant]
WO 2009079259 · 2009 [cited by applicant]
WO 2009086514 · 2009 [cited by applicant]
WO 2011153380 · 2011 [cited by applicant]
WO 2012099973 · 2012 [cited by applicant]
WO 20130123061 · 2013 [cited by applicant]
WO 20130154760 · 2013 [cited by applicant]
WO 2013166500 · 2013 [cited by applicant]
WO 20140011988 · 2014 [cited by applicant]
WO 2014055897 · 2014 [cited by applicant]
WO 2014134165 · 2014 [cited by applicant]
WO 2014144061 · 2014 [cited by applicant]
WO 2015143194 · 2015 [cited by applicant]
WO 2015164865 · 2015 [cited by applicant]
WO 2016054638 · 2016 [cited by applicant]
WO 2016057488 · 2016 [cited by applicant]
Donahue et al. Journal for Immuno Therapy of Cancer 5:20 DOI 10.1186/s40425-017-0220-y (Year: 2017). [cited by examiner]
Wilkie S, Picco G, Foster J, Davies D M, Julien S, Cooper L et al. Retargeting of human T cells to tumor-associated MUCI: the evolution of a chimeric antigen receptor. J Immunol 2008; 180(7): 4901-9. [cited by applicant]
Written Opinion, WO2016100985, Jul. 4, 2016. [cited by applicant]
Kiao-Song Zhong et al, “Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-mediated Tumor Eradication”, Molecular Therapy, vol. 18, No. 2, Feb. … [cited by applicant]
Xiao-Song Zhong et al, “Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-mediated Tumor Eradication”, Molecular Therapy, vol. 18, No. 2, Feb. … [cited by applicant]
Xu C, Lo A, Yammanuru A, Tallarico A S, Brady K, Murakami A et al. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PloS one 2010; 5(3): e… [cited by applicant]
Zavada J, Zavadova Z, Zatovicova M, Hyrsl L, Kawaciuk I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 2003; 89(6): 1067-71. [cited by applicant]
Zeytin H, Reali E, Zaharoff DA, Rogers CJ, Schlom J, Greiner J W. Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: N K cell recruitment to regional lymph nodes and priming of tumor-specific host … [cited by applicant]
Zhong, Xiao-Song, et al. “Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.” Molecular therapy 18.2 (2010): 413-420. [cited by applicant]
KakaAS, ShafferD R, HartmaierR, Leen AM, Lu A, Bear A, et al. Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. Journal of … [cited by applicant]
Kakarla S, Gottschalk S. CART cells for solid tumors: armed and ready to go? Cancer journal. 2014; 20:151-5. [cited by applicant]
Kalas M, Levine B L, Porter D L, Katz S, Grupp S A, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science translational … [cited by applicant]
Kershaw M H, Westwood J A, Parker L L, Wang G, Eshhar Z, Mavroukakis SA et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12(20 Pt 1): 6106-15. [cited by applicant]
Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxi… [cited by applicant]
Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, OosterwijkWakka J et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2… [cited by applicant]
Lancaster J A, Harris A L, Davidson S E, Logue J P, Hunter R D, Wycoff C C et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and progn… [cited by applicant]
Laughlin et al. Latent infection of KB cells with adeno-associated virus type 2. J Virol. 1986; 8(10): 515-524. [cited by applicant]
Lebkowski et al. Adeno-Associated Virus: a Vector System for Efficient Introduction and Integration of DNA into a Variety of Mammalian Cell Types. Mol and Cell Biol. 1988; 8(10): 3988-3996. [cited by applicant]
Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CDS T cell response. Journal of immunology. 2005; 175:2261-9. [cited by applicant]
Liao S Y, Aurelio O N, Jan K, Zavada J, Stanbridge E J. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer research 1997; 57(14): 2827-31. [cited by applicant]
Liao S Y, Brewer C, Zavada J, Pastorek J, Pastorekova S, Manetta A et al. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. … [cited by applicant]
Lo A S, Ma Q, Liu D L, Junghans R P. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res 2010; 16(10): 2769-80. [cited by applicant]
Lo A S, Xu C, Murakami A, Marasco WA. Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T-cells expressing a human anti-CAIX chimeric antigen receptor. Molecular Therapy—Oncol… [cited by applicant]
Lo, Agnes Shuk-Yee, et al. “Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.” Molecular Therapy—Oncolytics 1 (… [cited by applicant]
Long AH, Haso WM, Shern J F, Wanhainen K M, Murgai M, Ingaramo M, et al. 4-IBB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nature medicine. 2015; 21:581-90. [cited by applicant]
Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner M K. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006; 20(10): 1819… [cited by applicant]
Maher J, Brentjens R J, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002; 20(1): 70-5. [cited by applicant]
Mansour et al. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature. 1988; 336(6197):348-52. [cited by applicant]
Marasco et al.“Carbonic anhydrase IX: opportunities for immune-based approaches” Nov. 7, 2015. [cited by applicant]
Maude S L, Frey N, Shaw P A, Aplenc R, Barrett D M, Bunin N J, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England journal of medicine. 2014; 371:1507-17. [cited by applicant]
McLaughlin et al. Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol. 1988; 62:1963-73. [cited by applicant]
Milone MC, Fish JD, Carpenito C, Carroll RG, Binder G K, Teachey D et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.… [cited by applicant]
Miotti S, Negri D R, Valota 0, Calabrese M, Bolhuis R L, Gratama J W et al. Level of anti-mouseantibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer s… [cited by applicant]
Mirzabekov T, Kontos H, Farzan M, Marasco W, Sodroski J. Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCRS. Nat Biotechnol 2000; 18(6): 649-54. [cited by applicant]
Mor F, Cohen IR. IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis. Correlation with induction of Bcl-2. J Immunol 1996; 156(2): 515-22. [cited by applicant]
Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009; 183(7): 4169-75. [cited by applicant]
Pardoll D M. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer. 2012; 12:252-64. [cited by applicant]
Pastorekova S, Parkkila S, ParkkilaAK, Opaysky R, Zelnik V, Saarnio J et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenter… [cited by applicant]
Pegram et al. “Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning” Blood, The J. of Amer. Soc. Of Hematology 119. 18(2012):4133-4141. [cited by applicant]
Pegram H J, Park J H, Brentjens R J. CD28z CARs and armored CARs. Cancer J20I4; 20(2): 127-33. [cited by applicant]
Pegram, Hollie J., et al. “Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.” Blood, The Journal of the American Society of Hematology 119.18 (2012): 4133-41… [cited by applicant]
Saarnio J, Parkkila S, Parkkila AK, Waheed A, Casey M C, Zhou X Y et al. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highes… [cited by applicant]
Sadelain et al: The Basic Principles of Chimeric Antigen Receptor Design, Cancer Discovery, vo. 3, No. 4, Apr. 1, 2013, pp. 388-398. [cited by applicant]
Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21(2): 215-23. [cited by applicant]
Sadelain, Michel, Renier Brentjens, and Isabelle Rivière. “The basic principles of chimeric antigen receptor design.” Cancer discovery 3.4 (2013): 388-398. [cited by applicant]
Schaft N, Willemsen RA, de Vries J, Lankiewicz B, Essers B W, Gratama J W et al. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary huma… [cited by applicant]
Schwarzer A, Wolf B, Fisher J L, Schwaab T, Olek S, Baron U et al. Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokinetherapy. PloS one 20… [cited by applicant]
Sedlakova 0, Svastova E, Takacova M, Kopacek J, Pastorek J, Pastorekova S. Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Frontiers in physiology. 2014; 4:400. [cited by applicant]
Singh H, Figliola M J, Dawson M J, Huls H, Olivares S, Switzer K, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer research. 2011; 71:3… [cited by applicant]
Song D G, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C et al. In vivo persistence, tumor localization, and anti tumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-IBB). Cance… [cited by applicant]
Srivastava S, Riddell SR. Engineering CAR-T cells: Design concepts. Trends in immunology. 2015; 36:494-502. [cited by applicant]
Sui J, Aird DR, Tamin A, Murakami A, Yan M, Yammanuru A et al. Broadening of neutralization activity to directly block a dominant antibody-driven SARS coronavirus evolution pathway. PLoS pathogens 2008; 4(11): e1000197. [cited by applicant]
Thomas K R, Capecchi M R. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell. 1987; 51(3):503-512. [cited by applicant]
Topalian SL, Hodi F S, Brahmer JR, Gettinger S N, Smith D C, McDermott D F, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012; 366:2443-54. [cited by applicant]
TPO mailed Mar. 18, 2020. [cited by applicant]
Tratschin et al. A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol. 1984; 4(10):2072-… [cited by applicant]
Virgin H W, Wherry E J, Ahmed R. Redefining chronic viral infection. Cell. 2009; 138:30-50. [cited by applicant]
Wald O, Weiss I D, Wald H, Shoham H, Bar-Shavit Y, Beider K et al. IFN-gamma acts on T cells to induce N K cell mobilization and accumulation in target organs. J Immunol 2006; 176(8): 4716-29. [cited by applicant]
Wayne A Marasco et al: “Carbonic Anhydrdase IX: Opportunities for Immune-Based Approaches”. Nov. 7, 2015 (Nov. 7, 2015), Retrieved from the Internet: URL:http:/fwww.euikcs.com/kca/miami/does/h6-marasco.pdf. [cited by applicant]
Afreen et al. The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone, Heamatol Cancer Stem Cell Ther 7:1-17 (2014). [cited by applicant]
Agnes Shuk-Yee Lo et al. Regression of established renal cell carcinoma in nude mice using lentivirus-transdued human T cells expressing a human anti-CAIX chimeric antigen receptor, Oncolytics 1, 14003; doi: 10/1038/mto… [cited by applicant]
Brahmer, Julie R., et al. “Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.” New England Journal of Medicine 366.26 (2012): 2455-2465. [cited by applicant]
Jilaveanu et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nepthrectomy and sites of metastases, J Cancer Therapy 5:166-172 (2014). [cited by applicant]
Third Party Observation in European patent application 15828615.3 mailed by European Patent Office on Mar. 18, 2020. [cited by applicant]
Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11(10): 3714-21. [cited by applicant]
Bar E, Whitney PG, Moor K, Reise Sousa C, Leibund Gut-Landmann S. IL-1 7 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity 2014; 40(1): 117-27. [cited by applicant]
Blomer et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 1997; 71(9): 6641-9. [cited by applicant]
Carpenito C, Milone M C, Hassan R, Simonet J C, Lakhal M, Suhoski M M et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the… [cited by applicant]
Carpenter, Robert O., et al. “B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.” Clinical cancer research 19.8 (2013): 2048-2060. [cited by applicant]
Chang DK, Moniz R J, Xu Z, Sun J, Signoretti S, Zhu Q, et al. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Molecular cancer. 2015; 14… [cited by applicant]
Cotten et al. High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci U.S.A… [cited by applicant]
Dudley M E, Wunderlich J R, Robbins P F, Yang J C, Hwu P, Schwartzentruber D J et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298(5594): 850-4. [cited by applicant]
Dutcher JP. Recent developments in the treatment of renal cell carcinoma. Therapeutic advances in urology. 2013; 5:338-53. [cited by applicant]
EP examination report for EP Application No. 15828615.3, Apr. 6, 2018. [cited by applicant]
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015; 136:E359-8… [cited by applicant]
Frigola X, Inman BA, Lohse C M, Krco C J, Cheville J C, Thompson R H et al. Identification of a soluble form of B7-HI that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin … [cited by applicant]
GenBank accession No. GQ903548, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903549, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903550, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903551, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903552, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903553, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903554, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903555, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903556, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903557, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903558, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903559, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903560, Jul. 25, 2016. [cited by applicant]
GenBank accession No. GQ903561, Jul. 25, 2016. [cited by applicant]
Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. American journal of clinical pathology. 2010; 134:873-9. [cited by applicant]
Gill S, Tasian SK, Ruella M, Shestova 0, Li Y, Porter D L et al. Efficacy against human acute myeloid leukemia and myeloablation of normal hematopoiesis in a mouse model using chimeric antigen receptor-modified T cells.… [cited by applicant]
Grepin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E et al. The CXCL 7 I CXCRI/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer research 2014; 74(3): 873-83. [cited by applicant]
Han, et al. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous t-cell lymphoma; PLOS ONE, 2012, vol. 7, Issue 9, e44455. [cited by applicant]
Tarshman LC, Drake CG, Choueiri T K. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer immunology research. 2014; 2:1132-41. [cited by applicant]
Hilvo M, Baranauskiene L, Salzano A M, Scaloni A, Matulis D, Innocenti A et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 2008; 283(41): 27799-809. [cited by applicant]
Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B et al. Type 17 CDS+ T cells display enhanced antitumor immunity. Blood 2009; 114(3): 596-9. [cited by applicant]
Hombach A A, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 2012; 1( 4): 458-46… [cited by applicant]
Hombach A A, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 putperforms combined CD28-0X40 “superstimulation”. Molecular therapy: the journal of the American Society of Gene… [cited by applicant]
HombachA, Koch D, Sircar R, Heuser C, Diehl V, Kruis W et al. A chimeric receptor that selectively targets membrane-pound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther 1999; 6(2): 300-4. [cited by applicant]
Horwich et al. Synthesis of Hepadnavirus Particles That Contain Replication-Defective Duck Hepatitis B Virus Genomes in Cultured HuH7 Cells. J Virol. 1990; 64(2): 642-50. [cited by applicant]
Hoyos, Valentina, et al. “Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.” Leukemia 24.6 (2010): 1160-1170. [cited by applicant]
Inouye et al. Up-promoter mutations in the Ipp gene of [cited by applicant]
International Report on Patentability; WO2016100985; Jun. 20, 2017. [cited by applicant]
International Search Report, WO2016100985, Jul. 1, 2016. [cited by applicant]
Isakov N, Altman A. PKC-theta-mediated signal delivery from the TCR/CD28 surface receptors. Frontiers in immunology 2012; 3: 273. [cited by applicant]
Ivanov S, Liao S Y, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001; 158(3): 905-19. [cited by applicant]
John L B, Devaud C, Duong C P, Yong C S, Beavis P A, Haynes N M, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clinical cancer research: an official … [cited by applicant]
Blank, Christian, and Andreas Mackensen. “Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.” Cancer immunology, immunotherapy 56 (2007): 739… [cited by applicant]
Stillebroer et al. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. [cited by applicant]